Progress in the non-invasive evaluation of interstitial fibrosis and targeted therapy for pancreatic ductal adenocarcinoma

doi:10.3877/cma.j.issn.1674-0793.2022.06.014

Abstract

Abstract:

Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant solid tumors. Its important histological feature is the dynamically evolving tumor fibrotic stroma during tumor progression. Abundant extracellular matrix components promote tumor hypoxia and subsequent progression as well as drug resistance. An increasing number of studies have enriched the clinical understanding of biology and pathophysiology of interstitial fibrosis in PDAC. Emerging findings suggest that components of the tumor fibrotic stroma may have tumor-suppressive properties, making it more challenging to clarify its role. The use of imaging techniques to assess the degree of interstitial fibrosis in PDAC non-invasively has great potential, and some new stroma-targeted therapeutic approaches may help to improve the poor prognosis of patients in the future.

Key words: Pancreatic neoplasms, Interstitial fibrosis, Imaging evaluation, Targeted therapy

Siya Shi, Shiting Feng, Bingqi Shen. Progress in the non-invasive evaluation of interstitial fibrosis and targeted therapy for pancreatic ductal adenocarcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2022, 16(06): 443-447.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2022.06.014

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2022/V16/I06/443

References 35

[1]	Connor AA, Gallinger S. Pancreatic cancer evolution and heterogeneity: integrating omics and clinical data[J]. Nat Rev Cancer, 2022, 22(3): 131-142.
[2]	Ho WJ, Jaffee EM, Zheng L. The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities[J]. Nat Rev Clin Oncol, 2020, 17(9): 527-540.
[3]	Pang T, Wilson JS, Apte MV. Pancreatic stellate cells: what’s new?[J]. Curr Opin Gastroenterol, 2017, 33(5): 366-373.
[4]	Olivares O, Mayers JR, Gouirand V, et al. Collagen-derived proline promotes pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions[J]. Nat Commun, 2017, 8: 16031.
[5]	Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts[J]. Nat Rev Drug Discov, 2019, 18(2): 99-115.
[6]	Biffi G, Oni TE, Spielman B, et al. IL1-induced JAK/STAT signaling is antagonized by TGF-β to shape CAF heterogeneity in pancreatic ductal adenocarcinoma[J]. Cancer Discov, 2019, 9(2): 282-301.
[7]	Elyada E, Bolisetty M, Laise P, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts[J]. Cancer Discov, 2019, 9(8): 1102-1123.
[8]	Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2003, 21(17): 3296-3302.
[9]	Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer[J]. Brit J Cancer, 2002, 87(2): 161-167.
[10]	Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer[J]. Clin Cancer Res, 2015, 21(15): 3561-3568.
[11]	Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: randomized phase Ⅱstudy of PEGPH20 plus Nab-paclitaxel/gemcitabine versus Nab-paclitaxel/gemcitabine in patients with untreated, metastatic pancreatic ductal adenocarcinoma[J]. J Clin Oncol, 2018, 36(4): 359-366.
[12]	Ramanathan RK, McDonough SL, Philip PA, et al. Phase ⅠB/Ⅱ randomized study of FOLFIRINOX plus pegylated recombinant human hyaluronidase versus folfirinox alone in patients with metastatic pancreatic adenocarcinoma: SWOG S1313[J]. J Clin Oncol, 2019, 37(13): 1062-1069.
[13]	Van Cutsem E, Tempero MA, Sigal D, et al. Randomized phase Ⅲ trial of pegvorhyaluronidase Alfa with Nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma[J]. J Clin Oncol, 2020, 38(27): 3185-3194.
[14]	Bailey JM, Swanson BJ, Hamada T, et al. Sonic hedgehog promotes desmoplasia in pancreatic cancer[J]. Clin Cancer Res, 2008, 14(19): 5995-6004.
[15]	Catenacci DV, Junttila MR, Karrison T, et al. Randomized phase Ⅰb/Ⅱ study of gemcitabine plus placebo or Vismodegib, a Hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer[J]. J Clin Oncol, 2015, 33(36): 4284-4292.
[16]	De Jesus-Acosta A, Sugar EA, O’Dwyer PJ, et al. Phase 2 study of Vismodegib, a hedgehog inhibitor, combined with gemcitabine and Nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma[J]. Br J Cancer, 2020, 122(4): 498-505.
[17]	Principe DR, Doll JA, Bauer J, et al. TGFβ: duality of function between tumor prevention and carcinogenesis[J]. J Natl Cancer Inst, 2014, 106(2): djt369.
[18]	Melisi D, Garcia-Carbonero R, Macarulla T, et al. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer[J]. Br J Cancer, 2018, 119(10): 1208-1214.
[19]	Diop-Frimpong B, Chauhan VP, Krane S, et al. Losartan inhibits collagenⅠsynthesis and improves the distribution and efficacy of nanotherapeutics in tumors[J]. Proc Natl Acad Sci U S A, 2011, 108(7): 2909-2914.
[20]	Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase 2 clinical trial[J]. JAMA Oncol, 2019, 5(7): 1020-1027.
[21]	Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma[J]. Nat Genet, 2015, 47(10): 1168-1178.
[22]	Shi S, Liang C, Xu J, et al. The strain ratio as obtained by endoscopic ultrasonography elastography correlates with the stroma proportion and the prognosis of local pancreatic cancer[J]. Ann Surg, 2020, 271(3): 559-565.
[23]	Attiyeh MA, Chakraborty J, McIntyre CA, et al. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma[J]. Abdom Radiol (NY), 2019, 44(9): 3148-3157.
[24]	Torphy RJ, Wang Z, True-Yasaki A, et al. Stromal content is correlated with tissue site, contrast retention, and survival in pancreatic adenocarcinoma[J]. JCO Precis Oncol, 2018, 2018.
[25]	Erstad DJ, Sojoodi M, Taylor MS, et al. Fibrotic response to neoadjuvant therapy predicts survival in pancreatic cancer and is measurable with collagen-targeted molecular MRI[J]. Clin Cancer Res, 2020, 26(18): 5007-5018.
[26]	Hattori Y, Gabata T, Matsui O, et al. Enhancement patterns of pancreatic adenocarcinoma on conventional dynamic multi-detector row CT: correlation with angiogenesis and fibrosis[J]. World J Gastroenterol, 2009, 15(25): 3114-3121.
[27]	Hashimoto Y, Sclabas GM, Takahashi N, et al. Dual-phase computed tomography for assessment of pancreatic fibrosis and anastomotic failure risk following pancreatoduodenectomy[J]. J Gastrointest Surg, 2011, 15(12): 2193-2204.
[28]	Sofue K, Ueshima E, Masuda A, et al. Estimation of pancreatic fibrosis and prediction of postoperative pancreatic fistula using extracellular volume fraction in multiphasic contrast-enhanced CT[J]. Eur Radiol, 2022, 32(3): 1770-1780.
[29]	Wang Y, Chen ZE, Nikolaidis P, et al. Diffusion-weighted magnetic resonance imaging of pancreatic adenocarcinomas: association with histopathology and tumor grade[J]. J Magn Reson Imaging, 2011, 33(1): 136-142.
[30]	Noda Y, Goshima S, Tanaka K, et al. Findings in pancreatic MRI associated with pancreatic fibrosis and HbA1c values[J]. J Magn Reson Imaging, 2016, 43(3): 680-687.
[31]	Schawkat K, Eshmuminov D, Lenggenhager D, et al. Preoperative evaluation of pancreatic fibrosis and lipomatosis: correlation of magnetic resonance findings with histology using magnetization transfer imaging and multigradient echo magnetic resonance imaging[J]. Invest Radiol, 2018, 53(12): 720-727.
[32]	Yoon JH, Lee JM, Lee KB, et al. Pancreatic steatosis and fibrosis: quantitative assessment with preoperative multiparametric MR imaging[J]. Radiology, 2016, 279(1): 140-150.
[33]	Liu C, Shi Y, Lan G, et al. Evaluation of pancreatic fibrosis grading by multiparametric quantitative magnetic resonance imaging[J]. J Magn Reson Imaging, 2021, 54(5): 1417-1429.
[34]	Shi Y, Liu Y, Gao F, et al. Pancreatic stiffness quantified with MR elastography: relationship to postoperative pancreatic fistula after pancreaticoenteric anastomosis[J]. Radiology, 2018, 288(2): 476-484.
[35]	Itoh Y, Itoh A, Kawashima H, et al. Quantitative analysis of diagnosing pancreatic fibrosis using EUS-elastography (comparison with surgical specimens)[J]. J Gastroenterol, 2014, 49(7): 1183-1192.

Please choose a citation manager

Content to export